Albert O. R.
- Country
- Spain
- Department
- Servicio de Hematologia
Research Overview
- Safety and Pharmacokinetics of XMAB24306 with Daratumumab in Relapsed/Refractory Multiple Myeloma Patients
- Phase 1 Evaluation of GSK2857916 Combined with Standard of Care in Newly Diagnosed Multiple Myeloma Patients
- Safety Evaluation of CC-93269 in Patients with Relapsed and Refractory Multiple Myeloma
Data & Insights
Has run more than one trial at 333 of 651 partner sites.
Specializations
Multiple Myeloma Treatment
The investigator specializes in advancing therapies for multiple myeloma, with particular emphasis on novel treatment combinations and emerging therapeutic approaches.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- High-Risk Smoldering Multiple Myeloma
Primary focus includes evaluating innovative therapeutic combinations using bispecific antibodies, monoclonal antibodies, and targeted therapies.
Amyloidosis Research
Conducts clinical investigations in light chain amyloidosis, exploring novel therapeutic approaches for this rare plasma cell disorder.
- Systemic AL Amyloidosis
- Cardiac Involvement in AL Amyloidosis
- Treatment-Related Outcomes
Investigates safety and efficacy of targeted therapies in managing amyloidosis complications.
Therapeutic Innovation
Leads research in cellular therapy and immunotherapy approaches for hematologic malignancies.
- CAR T-Cell Therapy
- Combination Treatment Strategies
- Novel Drug Development
Explores innovative treatment pathways including maintenance therapy and stem cell transplantation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.